New Opportunities for Aspiring Nurses in Idaho with Joyce University Expansion

Flexible, hybrid nursing programs now available for Idaho residents

Aspiring nurses in Idaho can now prepare for RN licensure in as few as 20 months. Joyce University of Nursing and Health Sciences is broadening its hybrid pre- and post-licensure nursing programs to include Idaho.

Since 2022, Joyce University has expanded beyond Utah to include locations such as Arizona, Colorado, Missouri, New Mexico, Nevada, and now Idaho.

“This expansion is part of Joyce University’s ongoing commitment to make accelerated, high-quality nursing education available to communities across the US,” said Dr. John Smith-Coppes, President and CEO of Joyce University. “By eliminating barriers to entry such as prerequisites and waitlists plus offering online coursework with rich experiential focus, Joyce University is creating a flexible pathway for students at all stages of life while prioritizing excellence in quality, safety, and outcomes.”

With this expansion, students in Idaho can access a range of pre-licensure programs, such as the Associate of Science in Nursing (ASN), the Bachelor of Science in Nursing (BSN) and the Accelerated Bachelor of Science in Nursing (ABSN). Joyce University offers two post-licensure programs for those looking to further their nursing careers: the 4-semester online RN to BSN program and the 3-semester online MSN in Leadership program.

“Our programs are designed to meet the rising demand for well-trained nurses,” said Dr. Kelly McCullough, Dean of Nursing at Joyce University. “Our blended education model combines online lectures with hands-on labs and simulations and clinical experiences in their community, ensuring students have the flexibility they need while getting a high-quality education.”

Students participate in online lectures and attend scheduled skill immersions at the Joyce Johnson Center of Simulation at Joyce University’s Draper, UT campus. To build connections in their local communities and reduce travel, students complete clinical and practice experiences in their state of residence.

Enrollment for Idaho students is now open, with the next cohort starting in the Spring Semester on January 6, 2025.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version